Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers. The medicine, a monoclonal antibody, would stimulate the immune system to attack the protein–killing the tumors.

Alzheimer's Association. Saving Lives, Saving Money: Dividends for Americans investing in Alzheimer research. Falls Church, VA: The Lewin Group; 2004

Reference

Title
Saving Lives, Saving Money: Dividends for Americans investing in Alzheimer research
Publisher
The Lewin Group
Publication Date
2004
Authors
Alzheimer's Association

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • From 1975 to 1996, new cancer drugs increased life expectancy of cancer patients by about one year, at an estimated cost of $3,000—well below the estimated value of a statistical…  
  • A one percent reduction in lung, colorectal, breast, leukemia, pancreatic, and brain cancer mortality would reduce productivity costs by $814 million per year.  
  • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in development is designed to induce a powerful immune response to melanoma.  
  • Image-guided breast biopsy takes about 1/5 the of a surgical biopsy, reduces complications and allows women to commence daily activities in 1/2 the time that it takes after open surgery.…  
  • Death rates from breast cancer declined by an average of 2.3% per year between 1990 and 2002 because of earlier detection through screening, better awareness, and improved treatments.